Skip to main content

Table 2 Characteristics of the population

From: Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study

VariableControl period
N = 88
Treatment period
N = 89
p
Demographical data
  - Age (years)45 [26–58]45 [36–58]0.452
  - Male70 (77)77 (87)0.216
  - BMI (kg/m2)24 [20–28]25 [22–29]0.122
Admission
  - Polytrauma75 (80)80 (90)0.347
  - Non traumatic surgery13 (15)9 (10)0.347
SAPS 239 [27–48]40 [33–49]0.339
Characteristics of VAP
  - Time of occurrence (days after admission)5 [3–8]5 [2–7]0.234
  - Ventilator-acquired pneumonia75 (85)78 (88)0.639
  - Use of vasopressors41 (46)35 (39)0.329
  - PaO2/FiO2 < 2009 (10)7 (8)0.584
  - Bacteremia3 (3)2 (2)0.641
Renal function
  - CLCR the day of HAP-VAP (ml/min)199 [170–240]186 [160–223]0.013
  - CLCR the day of microbiological documentation (ml/min)191 [164–221]174 [147–200]0.013
Type of initial antimicrobial therapy
  - Piperacillin ± tazobactam35 (40)55 (62)0.003
  - Ceftriaxone or cefotaxime16 (18)12 (13)0.392
  - Ceftazidime or cefepime14 (16)3 (3)0.005
  - Amoxicillin ± clavulanic acid9 (10)13 (15)0.377
  - Cefazolin8 (9)3 (3)0.115
  - Meropenem6 (7)3 (3)0.297
Combined antimicrobial therapy
  - Association with aminoglycosides33 (38)27 (30)0.288
  - Association with quinolones6 (7)1 (1)0.050
  - Association with Gram-positive antibiotics10 (11)7 (8)0.415
Type of pathogen
  - Enterobacteriaceae47 (53)46 (52)0.818
  - Staphylococcus species40 (45)33 (37)0.258
  - Haemophilus influenzae19 (22)27 (30)0.185
  - Streptococcus/enterococcus species11 (13)15 (17)0.413
  - Non-fermenting GNB6 (7)11 (12)0.211
  - Others1 (1)1 (1)0.994
Polymicrobial infection29 (33)39 (44)0.137
De-escalation26 (30)29 (33)0.746
Total duration of antimicrobial therapy (days)7 [6–8]7 [6–7]0.026
Poor clinical outcome20 (23)9 (10)0.019
  - Therapeutic failure7 (8)4 (5)0.321
  - HAP-VAP recurrence13 (15)5 (6)0.039
Secondary acquisition of antimicrobial resistances4 (5)2 (2)0.382
Reported antibiotic side effects1 (1)0 (0)0.308
MV duration (days)12 [7–18]10 [5–18]0.420
ICU length of stay (days)22 [15–32]19 [14–30]0.216
Death in ICU7 (8)8 (9)0.805
  1. Results expressed as numbers (percentage) or median [25–75 interquartile]